FGP
BBIO icon

Freestone Grove Partners’s BridgeBio Pharma BBIO Stock Holding History

Freestone Grove Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-125,201
Closed -$9.58M – 990
2025
Q4 		$9.58M Buy
125,201
+31,732
+34% +$2.08M 0.07% 296
2025
Q3 		$4.85M Buy
+93,469
New +$4.56M 0.04% 336

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Grove Partners's BBIO Position: Q1 2026 in Review

Freestone Grove Partners sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 125,201 shares — an estimated $9.58M sold.

Freestone Grove Partners first reported a position in BBIO in Q3 2025 and held it in 2 quarters. The position peaked at $9.58M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Freestone Grove Partners reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 125,201 BridgeBio Pharma shares in Q1 2026, an estimated $9.58M.
  • Freestone Grove Partners first reported a position in BridgeBio Pharma in Q3 2025 and held it in 2 quarters.
  • Freestone Grove Partners's BridgeBio Pharma position peaked at $9.58M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.